Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alvogen launches first generic Exelon patch in US
The product will be marketed by Alvogen in three strengths (4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours) with Alvogen being the first filer for the
The product will be marketed by Alvogen in three strengths (4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours) with Alvogen being the first filer for the
IGI Laboratories president and CEO Jason Grenfell-Gardner said: "We believe our current pipeline of twenty-nine submissions, exclusive of our four partnered submissions, pending approval by the FDA now
The collaboration will focus on Redx’s existing pan-RAF inhibitor program, which is focused on colorectal cancer, the fourth most common cancer and the second most common cause of
Their approach, in which micro-liters of liquid containing a drug are instilled into the lung, distributed as a thin film in the predetermined region of the lung airway,
The company’s latest report states that this figure is almost triple that of the previous year, with just over $1.9bn raised from 62 deals in 2013, and almost
Financial terms of the deal were not disclosed. This is the first collaboration utilizing Novimmune’s new kappa-lambda bispecific antibody technology. The proprietary platform generates fully human antibodies which
The advanced infusion technology’s unique expandable tip increases drug delivery into the tumor while protecting healthy tissue. In clinical data recently published in the Journal of Vascular and
It enables preclinical development of Ocata’s proprietary photoreceptor progenitor product for the treatment of retinal degenerative diseases, such as retinitis pigmentosa (RP) and photoreceptor dystrophies. Ocata chief scientific
The acquisition will expand Xerox’s pharmacy solutions portfolio with an offering to help pharmaceutical companies drive product adoption and support patients in minimizing or eliminating financial and reimbursement
HS-110 is the Company’s first product candidate in a series of proprietary ImPACT™ based immunotherapies designed to stimulate patient’s own T-cells to attack cancer. Additionally, as the FDA